Connor, Clark & Lunn Investment Management (CC&L)
SCPH

Connor, Clark & Lunn Investment Management (CC&L)’s scPharmaceuticals SCPH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,532
Closed -$163K – 1656
2024
Q1 		$163K Buy
+32,532
New +$182K ﹤0.01% 1420
2023
Q3 		– Sell
-28,206
Closed -$287K – 1522
2023
Q2 		$287K Buy
+28,206
New +$294K ﹤0.01% 1118

Other funds holding SCPH

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SCPH Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of scPharmaceuticals (SCPH) in Q2 2024, closing a stake of 32,532 shares — an estimated $163K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SCPH in Q2 2023 and held it in 2 quarters. The position peaked at $287K in Q2 2023. 77 funds tracked by Wall St. Rank hold SCPH as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining scPharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 32,532 scPharmaceuticals shares in Q2 2024, an estimated $163K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in scPharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s scPharmaceuticals position peaked at $287K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.